2004; Dunn et al, 2005; Castanon et al, 2002; Sluzewska et al, 1996; Basterzi et al, 2005) . These results imply that depression could be a low-grade systemic inflammatory condition.
Central nervous system regulates the production of proinflammatory cytokines: TNF, IL-1, HMGB1, IL-6, and MIF through the efferent vagus nerve (Borovikova et al, 2000; Ulloa, 2005) . Acetylcholine, the principal vagus neurotransmitter, inhibits the production of proinflammatory cytokines through a mechanism dependent on the a7 nicotinic acetylcholine receptor subunit. Thus, vagus nerve stimulation controls the production of proinflammatory cytokines.
As VNS is of benefit in depression, vagus inhibits the production of proinflammatory cytokines, and patients with depression have elevated plasma and cerebrospinal fluid concentrations of these cytokines (Levine et al, 1999; Suarez et al, 2003) , I propose that the beneficial effect of VNS in depression is owing to its (VNS) inhibitory action on the production of proinflammatory cytokines. This can be verified by estimating plasma levels of various proinflammatory cytokines before and after VNS therapy and response. I also suggest that failure of VNS therapy, in some, could be due to its inability to suppress production of proinflammatory cytokines either because duration and/or strength of VNS is not sufficient. Thus, if this idea is true, correlation of VNS, depression, and plasma and cerebrospinal fluid cytokine profile may in turn be an interesting tool as suitable biomarkers to predict response and adequacy of VNS, and for screening of populations under risk for depression.
